Literature DB >> 15385376

Rapid development of severe interstitial pneumonia caused by epoprostenol in a patient with primary pulmonary hypertension.

Hiroshi Morimatsu1, Keiji Goto, Takashi Matsusaki, Hiroshi Katayama, Hiromi Matsubara, Tohru Ohe, Kiyoshi Morita.   

Abstract

A young woman with primary pulmonary hypertension developed severe interstitial pneumonia (IP) 5 days after induction of epoprostenol infusion. Although the pathogen involved was not identified, her IP was initially responsive to steroids, and discontinuation of steroid therapy caused the redevelopment of IP. After intensive treatment, including steroid therapy and inhaled nitric oxide, epoprostenol was successfully switched to prostaglandin E(1) infusion and she recovered. Epoprostenol infusion can cause a rapid severe IP, even soon after the induction of therapy. Clinicians should keep this syndrome in mind, especially when treating a severe case of IP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385376     DOI: 10.1213/01.ANE.0000130615.28893.52

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Flow cytometric characterization of the saphenous veins endothelial cells in patients with chronic venous disease and in patients undergoing bypass surgery: an exploratory study.

Authors:  Cláudia Torres; Rui Machado; Margarida Lima
Journal:  Heart Vessels       Date:  2019-06-21       Impact factor: 2.037

2.  Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice.

Authors:  Nelida Olave; Charitharth Vivek Lal; Brian Halloran; Vineet Bhandari; Namasivayam Ambalavanan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-28       Impact factor: 5.464

3.  Inhaled Pulmonary Vasodilators in Cardiac Surgery Patients: Correct Answer Is "NO".

Authors:  Fumito Ichinose; Warren M Zapol
Journal:  Anesth Analg       Date:  2017-08       Impact factor: 5.108

4.  Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay.

Authors:  Kristina T Kudelko; Kari Nadeau; Ann N Leung; Juliana Liu; François Haddad; Roham T Zamanian; Vinicio De Jesus Perez
Journal:  J Heart Lung Transplant       Date:  2010-06-08       Impact factor: 10.247

5.  Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome.

Authors:  Kimikazu Takeuchi; Kazuhiko Nakayama; Mitsumasa Okano; Naoki Tamada; Hideya Suehiro; Yuto Shinkura; Kenichi Yanaka; Hiroyuki Onishi; Hidekazu Tanaka; Toshiro Shinke; Noriaki Emoto; Ken-Ichi Hirata
Journal:  Respir Med Case Rep       Date:  2017-12-07

6.  Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.

Authors:  Ayako Chida-Nagai; Koichi Sagawa; Takao Tsujioka; Takanori Fujimoto; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Hirokuni Yamazawa; Naoki Masaki; Atsushi Manabe; Atsuhito Takeda
Journal:  Heart Vessels       Date:  2020-04-13       Impact factor: 2.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.